Table 3 Completed and ongoing clinical trials on patients with neurofibromatosis type 2
From: The genetic landscape and possible therapeutics of neurofibromatosis type 2
ID | Initiation Date | Phase | Nation | N | Disease | Treatment | Primary Outcome | Class of inhibitor | Mechanism of action | Status |
|---|---|---|---|---|---|---|---|---|---|---|
NCT02934256 | 7.2016 | 2 | China | 10 | NF2 VS | Icotinib | Volume of tumor | RTKs | EGFR inhibitor | Completed |
NCT02129647 | 4.2014 | 2 | USA | 13 | NF2 VS | Axitinib | Expression Levels of p-S6,p-ERK, p-AKT | RTKs | VEGFR1/2/3 inhibitor | Completed Has Results |
NCT02104323 | 1.2014 | 2 | China | 20 | NF2 VS | Endostatin | Volume of tumor | RTKs | VEGF expression inhibitor | Completed |
NCT01345136 | 7.2015 | 2 | USA | 4 | NF2 | Everolimus | VS volume | mTOR | Inhibits mTORC1 | Active, not recruiting |
NCT01490476 | 1.2012 | 2 | France | 10 | NF2 | Everolimus | VS volume | mTOR | Inhibits mTORC1 | Completed |
NCT01880749 | 6.2013 | 1 | USA | 5 | NF2 VS Meningioma | Everolimus | Proportions of VS and meningiomas after exposure | mTOR | Inhibits mTORC1 | Completed |
NCT01419639 | 10.2011 | 2 | USA | 10 | NF2 | Everolimus | Radiographic Response Change in Tumor Size | mTOR | Inhibits mTORC1 | Completed, has results |
NCT01767792 | 5.2013 | 2 | USA | 22 | NF2 Progressive VS | Bevacizumab | Hearing | RTKs | VEGF-A inhibitor | Completed Has Results |
NCT01207687 | 10.2010 | 2 | USA | 14 | NF2 VS | Bevacizumab | Hearing | RTKs | VEGF-A inhibitor | Completed Has Results |
NCT01125046 | 6.2010 | 2 | USA | 50 | Acoustic Schwannoma Meningioma Ependymoma NF1 NF2 Brain Tumor | Bevacizumab | Progression Free Survival | RTKs | VEGF-A inhibitor | Completed Has Results |
NCT04283669 | 2.2020 | 2 | USA | 19 | NF2 Progressive VS | Crizotinib | Volumetric response rate | RTKs | c-MET inhibitor | Active, not recruiting |
NCT02831257 | 8.2016 | 2 | USA | 18 | NF2 Meningioma | AZD2014 | Radiographic Response Rate | mTOR | mTOR kinase inhibitor | Completed Has Results |
NCT03071874 | 10.2017 | 2 | USA | 28 | Grade II/ III NF2-mutated meningiomas | AZD2014 | Progression Free Survival | mTOR | mTOR kinase inhibitor | Active, not recruiting |
NCT04374305 | 6.2020 | 2 | USA | 80 | NF2 VS | Brigatinib | Volumetric response rate | RTKs | ALK and EGFR inhibitor | Recruiting |
NCT02523014 | 8.2015 | 2 | USA | 124 | NF2 Gene Mutation | GSK2256098 | Progression free survival | FAK | FAK inhibitor | Recruiting |
NCT03095248 | 5.2017 | 2 | USA | 34 | NF2 VS Meningioma Ependymoma Glioma | Selumetinib | Hearing Response rate of NF2 related tumors | MEK | MEK1/2 inhibitor | Recruiting |
NCT03079999 | 6.2018 | 2 | USA | 300 | NF2 VS | Aspirin | Progressive free survival | Hippo pathway | Cyclooxygenase Inhibitor | Recruiting |
NCT01129193 | 1.2017 | 1 | USA | 44 | Solid tumors | AR-42 | Adverse events | AKT | Histone deacetylase inhibitor | Completed |
NCT02282917 | 12.2015 | 1 | USA | 7 | NF2 VS Meningioma | AR-42 | Ratio of Phospho-AKT | AKT | Histone deacetylase inhibitor | Terminated Has Results |
NCT05130866 | 6.2022 | 2/3 | USA | 89 | NF2 | AR-42 | Progressive free survival | AKT | Histone deacetylase inhibitor | Recruiting |
NCT00863122 | 6.2009 | 1 | USA | 26 | NF2 VS Auditory Tumor | Lapatinib | Lapatinib Plasma Concentrations | RTKs | EGFR/ ErbB2 Inhibitor | Completed Has Results |
NCT00973739 | 9.2009 | 2 | USA | 21 | NF2 VS | Lapatinib | Progression Free Survival | RTKs | EGFR/ ErbB2 Inhibitor | Completed Has Results |
NCT01201538 | 10.2010 | 2 | Canada | 2 | Growing VS | Nilotinib | Volume change of VS | RTKs | Bcr-Abl inhibitor | Terminated |
NCT00911248 | 7.2009 | 2 | USA | 11 | NF2 | PTC299 | Volume of tumor | RTKs | VEGFA inhibitor | Terminated |
NCT04085159 | 9.2019 | 1/2 | China | 100 | Schwannomatosis NF1 NF2 | Antigen-specific T cells CART/CTL and DCvac | Percentage of adverse effects | Immunotherapy | Immunotherapy | Recruiting |
NCT05228015 | 7.2022 | 1 | USA | 158 | NF2 Deficiency | IK-930 | Safety and tolerability | Hippo pathway | TEAD inhibitor | Recruiting |
NCT04857372 | 10.2021 | 1 | USA | 156 | Advanced Mesothelioma and Other Solid Tumors | IAG933 | Percentage of adverse effects | Hippo pathway | YAP/TEAD interaction inhibitor | Recruiting |